Moleculin Biotech, Inc. 8-K

What Happened Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on May 26, 2026 disclosing a Regulation FD corporate presentation. The company attached the presentation as Exhibit 99.1 and posted it on its website. The filing does not report earnings, executive changes, or other material transactions.

Key Details

• Filing date: May 26, 2026 (Form 8-K, Item 7.01 and 9.01).
• Exhibit included: 99.1 — Investor Presentation dated May 2026.
• The presentation was posted on the company’s corporate website under its investor materials.
• Cover page interactive data file included as Exhibit 104 (Inline XBRL).

Why It Matters This 8-K makes Moleculin’s May 2026 investor presentation publicly available, giving shareholders and potential investors direct access to the company’s latest corporate and pipeline information. While it is not an earnings report (no Item 2.02 disclosures) and does not announce management or transaction changes, the presentation may contain updates on strategy, programs, timelines or clinical progress that investors often use to assess near-term catalysts. Investors should review the attached Exhibit 99.1 for specific program or milestone details.